157 related articles for article (PubMed ID: 37670592)
1. Self-Assembled Multivalent Aptamer Drug Conjugates: Enhanced Targeting and Cytotoxicity for HER2-Positive Gastric Cancer.
Ma W; Yang Y; Liu Z; Zhao R; Wan Q; Chen X; Tang B; Zhou Y; Lin Y
ACS Appl Mater Interfaces; 2023 Sep; 15(37):43359-43373. PubMed ID: 37670592
[TBL] [Abstract][Full Text] [Related]
2. An Intelligent DNA Nanorobot with
Ma W; Zhan Y; Zhang Y; Shao X; Xie X; Mao C; Cui W; Li Q; Shi J; Li J; Fan C; Lin Y
Nano Lett; 2019 Jul; 19(7):4505-4517. PubMed ID: 31185573
[TBL] [Abstract][Full Text] [Related]
3. Biomimetic Nanoerythrosome-Coated Aptamer-DNA Tetrahedron/Maytansine Conjugates: pH-Responsive and Targeted Cytotoxicity for HER2-Positive Breast Cancer.
Ma W; Yang Y; Zhu J; Jia W; Zhang T; Liu Z; Chen X; Lin Y
Adv Mater; 2022 Nov; 34(46):e2109609. PubMed ID: 35064993
[TBL] [Abstract][Full Text] [Related]
4. The effects of T-DXd on the expression of HLA class I and chemokines CXCL9/10/11 in HER2-overexpressing gastric cancer cells.
Nakajima S; Mimura K; Matsumoto T; Thar Min AK; Ito M; Nakano H; Neupane P; Kanke Y; Okayama H; Saito M; Momma T; Watanabe Y; Hanayama H; Hayase S; Saze Z; Kono K
Sci Rep; 2021 Aug; 11(1):16891. PubMed ID: 34413454
[TBL] [Abstract][Full Text] [Related]
5. Copolymer micelles function as pH-responsive nanocarriers to enhance the cytotoxicity of a HER2 aptamer in HER2-positive breast cancer cells.
Shen Y; Zhang J; Hao W; Wang T; Liu J; Xie Y; Xu S; Liu H
Int J Nanomedicine; 2018; 13():537-553. PubMed ID: 29416334
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer.
Ishii T; Shitara K
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1193-1201. PubMed ID: 34543577
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer.
Mishima S; Shitara K
Expert Opin Biol Ther; 2021 Jul; 21(7):825-830. PubMed ID: 33798395
[No Abstract] [Full Text] [Related]
8. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective.
Aoki M; Iwasa S; Boku N
Gastric Cancer; 2021 May; 24(3):567-576. PubMed ID: 33646464
[TBL] [Abstract][Full Text] [Related]
9. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
[TBL] [Abstract][Full Text] [Related]
10. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
11. Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan.
Yin O; Iwata H; Lin CC; Tamura K; Watanabe J; Wada R; Kastrissios H; AbuTarif M; Garimella T; Lee C; Zhang L; Shahidi J; LaCreta F
Clin Pharmacol Ther; 2021 Oct; 110(4):986-996. PubMed ID: 33999422
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
Indini A; Rijavec E; Grossi F
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310
[TBL] [Abstract][Full Text] [Related]
13. Angiogenic Aptamer-Modified Tetrahedral Framework Nucleic Acid Promotes Angiogenesis In Vitro and In Vivo.
Zhao D; Liu M; Li J; Xiao D; Peng S; He Q; Sun Y; Li Q; Lin Y
ACS Appl Mater Interfaces; 2021 Jun; 13(25):29439-29449. PubMed ID: 34137587
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.
Bartsch R
Expert Opin Investig Drugs; 2020 Sep; 29(9):901-910. PubMed ID: 32701032
[TBL] [Abstract][Full Text] [Related]
15. Systemic delivery of aptamer-drug conjugates for cancer therapy using enzymatically generated self-assembled DNA nanoparticles.
Tran BT; Kim J; Ahn DR
Nanoscale; 2020 Nov; 12(45):22945-22951. PubMed ID: 33188383
[TBL] [Abstract][Full Text] [Related]
16. Aptamer nucleotide analog drug conjugates in the targeting therapy of cancers.
Li Y; Zhao J; Xue Z; Tsang C; Qiao X; Dong L; Li H; Yang Y; Yu B; Gao Y
Front Cell Dev Biol; 2022; 10():1053984. PubMed ID: 36544906
[TBL] [Abstract][Full Text] [Related]
17. Dramatic Response to Trastuzumab Deruxtecan Rechallenge in a Patient with HER2-Positive Gastric Cancer: A Case Report.
Ogata T; Fujita Y; Muro K
Am J Case Rep; 2022 Mar; 23():e935600. PubMed ID: 35241641
[TBL] [Abstract][Full Text] [Related]
18. Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure.
Antonarelli G; Corti C; Tarantino P; Salimbeni BT; Zagami P; Marra A; Trapani D; Tolaney S; Cortes J; Curigliano G
ESMO Open; 2023 Aug; 8(4):101608. PubMed ID: 37467660
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacological and clinical study results of trastuzumab deruxtecan (T-DXd, ENHERTU
Saito K; Kaneko R; Kamio T; Kamiyama E; Muto R; Sugihara M
Nihon Yakurigaku Zasshi; 2021; 156(1):47-51. PubMed ID: 33390481
[TBL] [Abstract][Full Text] [Related]
20. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
Takegawa N; Nonagase Y; Yonesaka K; Sakai K; Maenishi O; Ogitani Y; Tamura T; Nishio K; Nakagawa K; Tsurutani J
Int J Cancer; 2017 Oct; 141(8):1682-1689. PubMed ID: 28677116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]